Stay updated with breaking news from Lobe Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M for Altemia® ...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 ...
Lobe Sciences Ltd. ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company's lead clinical program, L-130, a proprietary stabilized...
Disclaimer IMPORTANT NOTICE. This presentation is an overview of Lobe Sciences Ltd. and is for information purposes only and should not be...
VANCOUVER, British Columbia — Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”), a North American Biopharmaceutical Company committed to…